» Articles » PMID: 26434514

Significance and Determinants of Cardiac Troponin I in Patients With Obstructive Hypertrophic Cardiomyopathy

Overview
Journal Am J Cardiol
Date 2015 Oct 6
PMID 26434514
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Serum cardiac troponins have been demonstrated to have important clinical implications in patients with hypertrophic cardiomyopathy (HC). However, little is known about their roles in patients with obstructive HC. The aim of this study was to explore the clinical significance and determinants of serum cardiac troponin I (cTnI) in patients with obstructive HC using cardiovascular magnetic resonance imaging. We investigated the relations between serum cTnI levels and clinical, echocardiographic, and cardiovascular magnetic resonance parameters and assessed the determinants of serum cTnI in 149 consecutive patients with obstructive HC. The median level of serum cTnI was 0.019 ng/ml (interquartile range 0.009 to 0.044). CTnI was elevated (≥0.04 ng/ml) in 42 (28%) of the overall cohort. Patients with elevated cTnI had greater maximum wall thickness (p <0.001), larger left ventricular mass index (LVMI, p <0.001), more frequency of left atrium diameter ≥50 mm (p = 0.020), higher plasma values of N-terminal pro-B-type natriuretic peptide (p <0.001), and less hypertension (p = 0.014). Serum cTnI levels were positively correlated with maximum wall thickness (r = 0.444, p <0.001), LVMI (r = 0.556, p <0.001), N-terminal pro-B-type natriuretic peptide (r = 0.305, p <0.001), left ventricular end-diastolic volume index (r = 0.246, p = 0.002), and left ventricular end-systolic volume index (r = 0.272, p = 0.001) but negatively with left ventricular ejection fraction (r = -0.180, p = 0.028). On multivariate analysis, LVMI was independently associated with both elevated cTnI (odds ratio 1.032, p = 0.001) and increasing serum cTnI levels (β = 0.556, p <0.001). In addition, the presence of hypertension was independently related to less likely elevated cTnI (odds ratio 0.307, p = 0.029) and decreasing levels of serum cTnI (β = -0.165, p = 0.015). In conclusion, levels of serum cTnI are elevated in a significant proportion of our patients. Serum cTnI is associated with multiple parameters of disease severity, suggesting its great significance in assessing cardiac remodeling in patients with obstructive HC. Left ventricular hypertrophy, as indicated by LVMI, is the major determinant of serum cTnI levels.

Citing Articles

Circulating Biomarkers in Hypertrophic Cardiomyopathy.

Matthia E, Setteducato M, Elzeneini M, Vernace N, Salerno M, Kramer C J Am Heart Assoc. 2022; 11(23):e027618.

PMID: 36382968 PMC: 9851432. DOI: 10.1161/JAHA.122.027618.


Association of NT-proBNP and hs-cTnT with Imaging Markers of Diastolic Dysfunction and Focal Myocardial Fibrosis in Hypertrophic Cardiomyopathy.

Chevalier C, Wendner M, Suling A, Cavus E, Muellerleile K, Lund G Life (Basel). 2022; 12(8).

PMID: 36013420 PMC: 9410236. DOI: 10.3390/life12081241.


Papillary and Trabecular Muscles Have Substantial Impact on Quantification of Left Ventricle in Patients with Hypertrophic Obstructive Cardiomyopathy.

Yang C, Xu H, Qiao S, Jia R, Jin Z, Yuan J Diagnostics (Basel). 2022; 12(8).

PMID: 36010378 PMC: 9407152. DOI: 10.3390/diagnostics12082029.


Significance and Determinants of Plasma Apelin in Patients With Obstructive Hypertrophic Cardiomyopathy.

Yang C, Zhang C, Jia R, Qiao S, Yuan J, Jin Z Front Cardiovasc Med. 2022; 9:904892.

PMID: 35783816 PMC: 9247182. DOI: 10.3389/fcvm.2022.904892.


Prognostic Significance of Initial r-Wave in Leads V1 and aVR Before PTSMA in Patients with Hypertrophic Obstructive Cardiomyopathy.

Jiang X, Qiao S Int J Gen Med. 2021; 14:9589-9598.

PMID: 34916839 PMC: 8670858. DOI: 10.2147/IJGM.S343050.